The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease

Hashimoto, Etsuko; Yatsuji, Saturu; Kaneda, Hidehiro; Yoshioka, Yoko; Taniai, Makiko; Tokushige, Katsutoshi; Shiratori, Keiko

doi:10.1016/j.hepres.2005.09.007

Cited by 101 publications

(114 citation statements)

References 17 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…[24][25][26][27][28] The likelihood of disease progression to advanced fibrosis or mortality increases in older patients with NAFLD. [29][30][31] Many recent studies have reported that male gender is a risk factor for fatty liver disease. 4 For example, in a study of 26,527 subjects undergoing medical checkups, the prevalence of NAFLD was 31% in men and 16% in women.…”

Section: Strength Of Recommendationmentioning

confidence: 99%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

Section: Strength Of Recommendationmentioning

confidence: 99%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

“…NASH is microscopically characterized by hepatic steatosis, lobular inflammation, ballooning degeneration of hepatocytes, Mallory bodies, and pericellular fibrosis [18]. Furthermore, recent studies have suggested that NASH may progress to fibrosis, cirrhosis, and hepatocellular carcinoma [2,9,25,34]. The prevalence of NASH is 2.1-6.3% in the general populations, and in many patients, NASH is associated with obesity, diabetes mellitus, and hyperlipidemia [3,22,27].…”

Section: Introductionmentioning

confidence: 99%

Insulin Resistance, Steatohepatitis, and Hepatocellular Carcinoma in a New Congenic Strain of Fatty Liver Shionogi (FLS) Mice with the Lepob Gene

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Based on annual health checks, the prevalence of fatty liver diagnosed by ultrasonography increased from 10% in 1980 to 20-40% in 2000 among adults. Thus, nonalcoholic fatty liver disease (NAFLD) is now emerging as the most common liver disease in Japan (2,3). The recent worldwide rise in the number of patients with nonalcoholic steatohepatitis (NASH) tends to parallel the increase in metabolic syndrome, which includes obesity, type 2 diabetes and hyperlipidemia (4).…”

Section: Introductionmentioning

confidence: 99%

Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue

Ueno

Torimura²,

Nakamura³

et al. 2009

Int J Mol Med

View full text Add to dashboard Cite

Abstract. We examined whether or not epigallocatechin-3-gallate (EGCG) improves liver injury of nonalcoholic steatohepatitis (NASH) model mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue. nSREBP-1c transgenic C57BL6 mice aged 30 weeks were divided into group 1 (no treatment), group 2 (ascorbic acid alone), group 3 (ascorbic acid and 0.05% EGCG), and group 4 (ascorbic acid and 0.1% EGCG). At 42 weeks, we performed measurement of liver weight to body weight, biochemical assays, morphometry of liver specimens, immunohistochemistry for 8-hydro-2'-deoxyguanosine (8-OhdG), and Western blotting for insulin and TNF-· signalings. Ratio of liver weight to body weight in the high dose EGCG-treated group (group 4) was significantly lower than those of groups 1 and 2 (p<0.05 and <0.01, respectively). Blood ALT, glucose, total cholesterol, and triglyceride levels of group 4 were significantly low compared with those of the EGCGnon-treated group (groups 1 and 2) (p<0.05, respectively). The degrees of steatosis, inflammation, ballooning hepatocytes and Mallory-Denk bodies in group 4 significantly improved compared with those in other groups (p<0.05, respectively). The 8-OhdG immunolocalization in liver tissues of the group 4 obviously decreased compared with those of groups 2 and 3. For Western blotting, the expressions of insulin receptor substrate-1 (IRS-1) and phosphorylated IRS-1 (pIRS-1) in liver tissues of group 4 increased compared with those of groups 2 and 3. On the other hand, the expressions of pAkt, pIKKß and pNF-κB decreased compared with those of groups 2 and 3. From these results, EGCG reduces inflammation, insulin resistance and oxidative stress, and suppresses liver injury in nSREBP-1c transgenic mice. IntroductionAlthough the obesity epidemic is a worldwide phenomenon, the severity of the epidemic differs greatly from region to region. The prevalence of obesity among Japanese adults is 3.4% in males and 3.8% in females, and is around one tenth of that in the USA (1). In addition, currently in Japan almost 30% of adult males and females over 50 years old are obese. This rising incidence of obesity parallels the dramatic increase in fatty liver in these age groups. Based on annual health checks, the prevalence of fatty liver diagnosed by ultrasonography increased from 10% in 1980 to 20-40% in 2000 among adults. Thus, nonalcoholic fatty liver disease (NAFLD) is now emerging as the most common liver disease in Japan (2,3). The recent worldwide rise in the number of patients with nonalcoholic steatohepatitis (NASH) tends to parallel the increase in metabolic syndrome, which includes obesity, type 2 diabetes and hyperlipidemia (4).NAFLD mainly comprises of simple steatosis that is considered benign, however some patients have nonalcoholic steatohepatitis (NASH), which is a clinicopathological entity characterized by the development of hepatic histological changes resembling those induced by excessive alcohol intake that occur in the absence of alcohol abuse (5). Some patients w...

show abstract

The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease

Cited by 101 publications

References 17 publications

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Insulin Resistance, Steatohepatitis, and Hepatocellular Carcinoma in a New Congenic Strain of Fatty Liver Shionogi (FLS) Mice with the Lepob Gene

Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue

Contact Info

Product

Resources

About